Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.

@article{Villanueva2014LongtermSA,
  title={Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.},
  author={Vicente Villanueva and Jos{\'e} Mar{\'i}a Serratosa and Edelmira Guillam{\'o}n and Mercedes Garc{\'e}s and Beatriz Gonz{\'a}lez Gir{\'a}ldez and M Toledo and Javier Salas-Puig and Franscisco Javier L{\'o}pez Gonz{\'a}lez and Javier A. Flores and Juan Jes{\'u}s Rodriguez-Uranga and Ascensi{\'o}n Castillo and Jos{\'e} Angel Mauri and J. L. Camacho and Elena L{\'o}pez-Gom{\'a}riz and Pau Giner and Nerea Torres and Juan Palau and A. Molins},
  journal={Epilepsy research},
  year={2014},
  volume={108 7},
  pages={1243-52}
}
BACKGROUND Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed as adjunctive therapy in adults with partial-onset or focal seizures. OBJECTIVE To evaluate in a clinical practice setting the long-term efficacy and safety of ESL in patients with focal seizures. METHODS ESLIBASE was a retrospective study that included all patients with focal seizures who started ESL between January 2010 and July 2012 at 12 hospitals. ESL was prescribed individually according to real-life… CONTINUE READING